-- The session will address the critical challenges of achieving precise extrahepatic delivery, focusing on the engineering of lipid nanoparticles (LNPs) for lung cancer gene therapy.
Advanced LNP Engineering for Pulmonary Applications
As mRNA therapeutics evolve beyond systemic vaccines into localized oncology treatments, the primary bottleneck remains the delivery efficiency of non-viral platforms. This webinar will be led by Dr. Simone Pinto Carneiro, a group leader at Ludwig-Maximilians-University (LMU) of Munich. With over 13 years of expertise in RNA-lipid nanoparticles, Dr. Carneiro will share her team's latest progress in targeting KRAS mutations via inhalable delivery systems.
The presentation will delve into the technicalities of lipid nanoparticle (LNP) formulation and characterization. "Optimizing LNPs is not merely about encapsulation; it is about the strategic potential of CRISPR/Cas9-LNPs as inhalable therapeutics, providing a non-invasive, localized approach to treat lung tumors," states Dr. Carneiro.
Expanding the Nanoplatform Ecosystem
To meet the diverse requirements of modern RNA research, Creative Biolabs has integrated a multifaceted custom mRNA delivery vehicle development service. This platform extends beyond standard lipids to include polymer-based, hybrid, and biomimetic carriers.
Polymer-based Vectors: Designed for chemical tunability and controlled release.
Hybrid Systems: Combining the structural stability of polymeric cores with lipid shells for high cellular entry.
Enveloped Virus-Like Particles (eVLPs): Leveraging viral fusogenic properties to penetrate difficult-to-transfect cell types without the risks of replication-competent viruses.
Technical Analysis: Optimizing Delivery Success
The transition from R&D to preclinical success requires rigorous attention to the following parameters:
Vehicle Selection: While LNPs are the current gold standard, custom eVLPs may provide superior T-cell activation in cancer vaccine contexts. For specific targeting of dendritic cells (DCs), mannose-functionalized LNPs are often employed.
Stability and Scale-up: Addressing stability involves precise PEGylation strategies and the fine-tuning of Zeta Potential and PDI (Polydispersity Index) to meet stringent CMC requirements.
Payload Versatility: Specialized hybrid vectors are increasingly utilized to condense large-scale self-amplifying RNA (saRNA), ensuring high-efficiency protection and sustained expression from a lower initial dose.
Webinar Information:
Time: 10AM EDT on May 19, 2026
Title: Optimization of Lipid Nanoparticles for CRISPR/Cas9 Delivery
Lead Speaker: Simone Pinto Carneiro, Ph.D.
Registration: Access the latest schedule and register on the official event page.
About
Creative Biolabs is a global leader in mRNA technology, offering a comprehensive suite of solutions from high-purity synthesis to advanced vehicle formulation. To foster global scientific collaboration, Creative Biolabs frequently invites distinguished researchers to share their latest breakthroughs through free technical sessions.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://mrna.creative-biolabs.com/
Release ID: 89188736
Google
RSS